Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 37NIH 11INDUSTRY 10NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Conditions

Respiratory Distress Syndrome 1Pneumonia 1Bronchiolitis Obliterans 1

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Etanercept × Clear all
NCT00029328 2015-03-25

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

FDA Office of Orphan Products Development

Phase 1/2 Completed
15 enrolled

Bronchiolitis Obliterans, Pneumonia, Respiratory Distress Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡